广西着力建设面向东盟的重要生物医药制造基地

Core Viewpoint - The Guangxi government has issued policies to promote the high-quality development of the biopharmaceutical industry, aiming to enhance specialization, aggregation, and intelligence in the sector, and to establish Guangxi as a significant biopharmaceutical manufacturing base for ASEAN [1] Group 1: R&D Innovation - Guangxi supports R&D innovation in the biopharmaceutical field, encouraging collaboration between enterprises and academic institutions to establish key laboratories and clinical research centers [1] - Financial support of no less than 50 million yuan is provided for newly recognized national key laboratories led by Guangxi [1] - Enterprises are incentivized to increase R&D investment, with subsidies based on the increase in R&D expenditure [1] - Support for clinical trial applicants includes up to 3 million yuan for Phase II and 5 million yuan for Phase III clinical trials for Class I innovative drugs [1] Group 2: Key Technology Development - The Guangxi technology plan includes support for the development of rare and endangered traditional Chinese medicine resources and marine biomedicine [2] - Financial support of up to 1.5 million yuan is available for generic drugs that meet specific criteria, with up to 4 million yuan for those requiring bioequivalence testing [2] Group 3: Market Development - Support is provided for establishing high-quality breeding bases and quality management standards for traditional Chinese medicine [3] - Financial incentives are available for biopharmaceutical companies achieving positive growth, with a focus on cultivating specialized and high-quality enterprises [3] - Companies are encouraged to expand into international markets, with support of up to 3 million yuan for those obtaining overseas listing qualifications [3] Group 4: Industrialization Support - Financial support is available for companies obtaining national drug or medical device registration, with varying amounts based on the classification and scale of production [4] - Support for key core technology industrialization is provided at 15% of fixed asset investment, with a cap of 20 million yuan per project [4] - The establishment of specialized pharmaceutical industrial parks is encouraged to enhance industry concentration [4] Group 5: Mechanism Improvement - The government prioritizes inspection, registration, and approval for projects included in major national and regional R&D plans [5] - Efforts are made to improve the efficiency of review and approval processes, as well as to broaden financing channels for the biopharmaceutical industry [5]